Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice

Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg once daily is recommended as a starting and maintenance do...

Descripción completa

Detalles Bibliográficos
Autores principales: Gooderham, Melinda J., Pink, Andrew E., Simpson, Eric L., Silverberg, Jonathan I., Güler, Erman, Watkins, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442301/
https://www.ncbi.nlm.nih.gov/pubmed/37482564
http://dx.doi.org/10.1007/s13555-023-00948-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442301/
https://www.ncbi.nlm.nih.gov/pubmed/37482564
http://dx.doi.org/10.1007/s13555-023-00948-6

Ejemplares similares